#Sweden #Lund #TFS HealthScience #Katarina Ageborg #Markus Granlund

TFS HealthScience's New Leadership

TFS HealthScience, a prominent global Contract Research Organization (CRO), has announced some significant leadership changes that aim to enhance its strategic direction and operational excellence. As of February 25, 2025, Katarina Ageborg has been appointed as the Chairwoman of the Board of Directors, while Markus Granlund will step in as the Interim CEO. This transition represents an exciting new chapter for TFS, which is committed to advancing global health and well-being through innovative treatments.

Expertise and Vision

Katarina Ageborg brings over 25 years of leadership experience in the life sciences sector, significantly from her time at AstraZeneca where she was part of the global executive team. Her strategic expertise is expected to be of immense value to TFS as it aims to bolster its global presence and cultivate stronger customer relations. She emphasizes governance and patient-centric innovation, pointing towards her intent to guide the company into a prosperous future that focuses on both innovation and customer satisfaction.

On the other hand, Markus Granlund, who has been a member of TFS's Board since October 2024, brings extensive experience in managing international operations. Previously, he served for over 16 years at Semcon, including 13 years as its CEO. Granlund's background in global team management and operational excellence will ensure a smooth transition, reinforcing the company’s commitment to delivering high-quality service and innovative solutions. He highlights, “I am excited to contribute to TFS's growth alongside our talented teams as we continue to fortify the company’s standing within the sector.”

Commitment to Quality and Innovation

Under the new leadership, TFS plans to boost its scientific expertise and operational excellence while expanding its capabilities in key therapeutic areas. By focusing on innovation and strategic partnerships, the company aims to provide high-quality, flexible solutions that lead to significant advancements in clinical research.

Granlund further adds, “This leadership change is part of our continued momentum to ensure that TFS remains a trusted partner for biotechnology and pharmaceutical companies around the globe.” The organization is dedicated to delivering top-notch clinical research services, fostering innovation, and keeping patients at the forefront of its mission.

About TFS HealthScience

TFS HealthScience is an international CRO that collaborates with biopharmaceutical companies to advance innovative treatments and improve patient outcomes. With a team of nearly 700 professionals across 40 countries, TFS, alongside its strategic partners, provides tailored resource solutions and clinical development services across specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. Through its commitment to empowering partners and enriching lives, TFS combines global reach with the agility of a mid-sized CRO, delivering flexible solutions that respond adeptly to the evolving needs of the healthcare landscape.

For more details, visit TFS HealthScience.